Previous clinical trials have shown that N-acetylcysteine (a thiol-based antioxidant, a precursor of glutathione) and sulforaphate (an activator of Nrf2) are not so effective in COPD, as noted above. Here, NFE2L2 is linked to chronic obstructive pulmonary disease.